These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 17667592

  • 1. The geldanamycin analogue 17-allylamino-17-demethoxygeldanamycin inhibits the growth of GL261 glioma cells in vitro and in vivo.
    Newcomb EW, Lukyanov Y, Schnee T, Esencay M, Fischer I, Hong D, Shao Y, Zagzag D.
    Anticancer Drugs; 2007 Sep; 18(8):875-82. PubMed ID: 17667592
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J, Pham NA, Cao MP, Hedley DW.
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [Abstract] [Full Text] [Related]

  • 3. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J, Penders C, Pink M, Read MA, Sang J, Woodward C, Zhang Y, Grayzel DS, Wright J, Barrett JA, Palombella VJ, Adams J, Tong JK.
    Proc Natl Acad Sci U S A; 2006 Nov 14; 103(46):17408-13. PubMed ID: 17090671
    [Abstract] [Full Text] [Related]

  • 4. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
    Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, Gius D.
    Cancer Res; 2003 Dec 15; 63(24):8984-95. PubMed ID: 14695217
    [Abstract] [Full Text] [Related]

  • 5. Potent triazolothione inhibitor of heat-shock protein-90.
    Feldman RI, Mintzer B, Zhu D, Wu JM, Biroc SL, Yuan S, Emayan K, Chang Z, Chen D, Arnaiz DO, Bryant J, Ge XS, Whitlow M, Adler M, Polokoff MA, Li WW, Ferrer M, Sato T, Gu JM, Shen J, Tseng JL, Dinter H, Buckman B.
    Chem Biol Drug Des; 2009 Jul 15; 74(1):43-50. PubMed ID: 19519743
    [Abstract] [Full Text] [Related]

  • 6. High anti tumor activity against rhabdomyosarcoma cells and low normal cells cytotoxicity of heat shock protein 90 inhibitors, with special emphasis on 17-[2-(pyrrolidin-1-yl)ethyl]-aminno-17-demethoxygeldanamycin.
    Lukasiewicz E, Miekus K, Kijowski J, Gozdzik J, Wilusz M, Bobis-Wozowicz S, Wiecha O, Majka M.
    J Physiol Pharmacol; 2009 Sep 15; 60(3):161-6. PubMed ID: 19826195
    [Abstract] [Full Text] [Related]

  • 7. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells.
    Schumacher JA, Crockett DK, Elenitoba-Johnson KS, Lim MS.
    Proteomics; 2007 Aug 15; 7(15):2603-16. PubMed ID: 17610208
    [Abstract] [Full Text] [Related]

  • 8. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L.
    Clin Cancer Res; 2003 Oct 15; 9(13):4961-71. PubMed ID: 14581371
    [Abstract] [Full Text] [Related]

  • 9. The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis.
    Dello Russo C, Polak PE, Mercado PR, Spagnolo A, Sharp A, Murphy P, Kamal A, Burrows FJ, Fritz LC, Feinstein DL.
    J Neurochem; 2006 Dec 15; 99(5):1351-62. PubMed ID: 17064348
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
    Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, Workman P.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):7023-32. PubMed ID: 16203796
    [Abstract] [Full Text] [Related]

  • 11. Geldanamycin and its analog induce cytotoxicity in cultured human retinal pigment epithelial cells.
    Wu WC, Wu MH, Chang YC, Hsieh MC, Wu HJ, Cheng KC, Lai YH, Kao YH.
    Exp Eye Res; 2010 Aug 01; 91(2):211-9. PubMed ID: 20493187
    [Abstract] [Full Text] [Related]

  • 12. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
    Yu W, Rao Q, Wang M, Tian Z, Lin D, Liu X, Wang J.
    Leuk Res; 2006 May 01; 30(5):575-82. PubMed ID: 16213582
    [Abstract] [Full Text] [Related]

  • 13. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.
    Yin X, Zhang H, Burrows F, Zhang L, Shores CG.
    Clin Cancer Res; 2005 May 15; 11(10):3889-96. PubMed ID: 15897590
    [Abstract] [Full Text] [Related]

  • 14. Geldanamycin induces mitotic catastrophe and subsequent apoptosis in human glioma cells.
    Nomura M, Nomura N, Newcomb EW, Lukyanov Y, Tamasdan C, Zagzag D.
    J Cell Physiol; 2004 Dec 15; 201(3):374-84. PubMed ID: 15389545
    [Abstract] [Full Text] [Related]

  • 15. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM.
    Cancer Chemother Pharmacol; 2005 Aug 15; 56(2):126-37. PubMed ID: 15841378
    [Abstract] [Full Text] [Related]

  • 16. Protection of murine neural progenitor cells by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin in the low nanomolar concentration range.
    Wang G, Krishnamurthy K, Tangpisuthipongsa D.
    J Neurochem; 2011 May 15; 117(4):703-11. PubMed ID: 21395580
    [Abstract] [Full Text] [Related]

  • 17. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism.
    McCollum AK, Teneyck CJ, Sauer BM, Toft DO, Erlichman C.
    Cancer Res; 2006 Nov 15; 66(22):10967-75. PubMed ID: 17108135
    [Abstract] [Full Text] [Related]

  • 18. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R, Ohyashiki JH, Kobayashi C, Hamamura R, Zhang Y, Hirano T, Ohyashiki K.
    Cancer Lett; 2009 Oct 18; 284(1):62-70. PubMed ID: 19464103
    [Abstract] [Full Text] [Related]

  • 19. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
    Jeon YK, Park CH, Kim KY, Li YC, Kim J, Kim YA, Paik JH, Park BK, Kim CW, Kim YN.
    J Pathol; 2007 Oct 18; 213(2):170-9. PubMed ID: 17768706
    [Abstract] [Full Text] [Related]

  • 20. Geldanamycin induces G2 arrest in U87MG glioblastoma cells through downregulation of Cdc2 and cyclin B1.
    Nomura N, Nomura M, Newcomb EW, Zagzag D.
    Biochem Pharmacol; 2007 May 15; 73(10):1528-36. PubMed ID: 17324379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.